Gengos Andrew
Transaction: 07/16/2026
BUY
Change
+650,000
Price
$4.78
Filing
07/17/2026
Type
BUY
Immuneering Corporation
IMRX • Biotechnology
$3.73
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$241.25M
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Healthy liquidity · 17.5Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:58 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$3.73
Change0.00%
Shares Out64.68M
Market Cap$241.25M
Enterprise Value$91.35M
52W Range3.00 - 10.08
Beta0.37
P/E-4.21
P/S668.36
P/B1.26
P/FCF-0.01
EV/Sales253.07
Price$3.73
Change0.00%
Shares Out64.68M
Market Cap$241.25M
Enterprise Value$91.35M
52W Range3.00 - 10.08
Beta0.37
P/E-4.21
P/S668.36
P/B1.26
P/FCF-0.01
EV/Sales253.07
EV/EBITDA-1.44
EV/FCF-0.00
Earnings Yield-23.74%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.02
Current Ratio17.50
Quick Ratio17.50
Revenue 5Y-100.00%
Target$15.50
Target Upside315.55%
Target Median$15.50
Target Range14.00 - 17.00
Volume1.08M
Avg Volume1.27M
EPS Surprise0.09
Investment DNA
How strong this company looks for long-term investors
42
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
92/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 17.5Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 11 analyst votes · 2026-10-20
82/100
Bullish
Bullish
7
Hold
4
Bearish
0
Price Target
2026-08-14
Low
$12.00
Mean
$14.33
Median
$14.00
High
$17.00
Insider Transactions
Recent executive and insider activity
Gengos Andrew
Transaction: 07/16/2026
OTHER
Change
0
Price
Not reported
Filing
07/16/2026
Type
OTHER
Zeskind Benjamin J.
Transaction: 06/23/2026
BUY
Change
+2,400
Price
$4.56
Filing
06/24/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Gengos Andrew | BUY | +650,000 | $4.78 | 07/16/2026 | 07/17/2026 |
| Gengos Andrew | OTHER | 0 | Not reported | 07/16/2026 | 07/16/2026 |
| Zeskind Benjamin J. | BUY | +2,400 | $4.56 | 06/23/2026 | 06/24/2026 |
| Hall Brett Matthew | BUY | +6,035 | $4.15 | 06/15/2026 | 06/16/2026 |
| Feinberg Peter | BUY | +33,350 | $4.12 | 06/11/2026 | 06/11/2026 |
| KEATING LAURIE | BUY | +33,350 | $4.12 | 06/11/2026 | 06/11/2026 |
| CARPENTER ROBERT J | BUY | +33,350 | $4.12 | 06/11/2026 | 06/11/2026 |
| HAUSMAN DIANA | BUY | +33,350 | $4.12 | 06/11/2026 | 06/11/2026 |
| Schall Thomas J. | BUY | +33,350 | $4.12 | 06/11/2026 | 06/11/2026 |
| Neufeld Leah R | BUY | +3,628 | $4.29 | 03/13/2026 | 03/17/2026 |
| Zeskind Benjamin J. | BUY | +688,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Neufeld Leah R | BUY | +140,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Morales Mallory | BUY | +140,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Matushansky Igor | BUY | +140,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Hall Brett Matthew | BUY | +344,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Brakewood Harold Eugene | BUY | +140,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Bookman Michael | BUY | +176,000 | $4.91 | 02/03/2026 | 02/05/2026 |
| Brakewood Harold Eugene | BUY | +5,250 | $4.76 | 01/16/2026 | 01/21/2026 |
| Schall Thomas J. | BUY | +21,645 | $4.67 | 01/15/2026 | 01/20/2026 |
| Hall Brett Matthew | BUY | +2,298 | $4.57 | 01/15/2026 | 01/16/2026 |